AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Retinol dehydrogenase 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IZV5

UPID:

RDH10_HUMAN

Alternative names:

Short chain dehydrogenase/reductase family 16C member 4

Alternative UPACC:

Q8IZV5

Background:

Retinol dehydrogenase 10 (RDH10), also known as Short chain dehydrogenase/reductase family 16C member 4, plays a pivotal role in the metabolism of vitamin A. It specifically catalyzes the conversion of all-trans-retinol to all-trans-retinal, a critical reaction in the visual cycle and vitamin A metabolism, with a marked preference for NADP. Unlike other enzymes in its family, RDH10 does not act on 11-cis-retinol, 9-cis-retinol, or 13-cis-retinol.

Therapeutic significance:

Understanding the role of Retinol dehydrogenase 10 could open doors to potential therapeutic strategies. Its specific activity in vitamin A metabolism suggests its involvement in visual function and possibly in disorders related to vitamin A deficiency or excess.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.